Palisade Bio, Inc. PALI
At closeNov 11, 2026, 7:49 PM EST
After hours · Nov 11, 7:49 PM ET
- YTD
- -50.21%
- 1 year
- -35.71%
- Market cap
- 203.90M
- EPS (ttm)
- 0.60
- Shares out
- 2.77M
- P/E ratio
- 1.95
- Forward P/E
- -0.19
- YTD return
- -50.21%
- 1-year return
- -35.71%
- Volume
- 2.97M
- Avg volume
- 3.10M
- Open
- 1.11
- Previous close
- 1.13
- Day's range
- 1.11 – 1.19
- 52-week range
- 1.08 – 2.86
- Beta
- 1.33
- Price target
- 30.33 (+2492.6%)
5D -0.08 (-6.61%)
Key statistics
- Enterprise value
- -8.24M
- PEG ratio
- 0.00
- Price / book
- 0.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -7.66M
- Total cash
- 11.35M
- Total debt
- 503.00K
- Return on equity
- -110.09%
- Short % of float
- 3.27%
- 50-day average
- 2.61
- 200-day average
- 4.17
Analyst view
- Target (low)
- 8.00
- Target (mean)
- 30.33
- Target (high)
- 45.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -2.58.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -2.32 | — | — |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | -3.32 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -4.59 | — | — |
| Mar 26, 2024 | Dec 1, 2023 | 0.00 | -3.75 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -7.35 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -7.95 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | Brookline Capital | init | — | Buy |
| Nov 13, 2024 | Maxim Group | main | Buy | Buy |
| May 1, 2024 | Maxim Group | reit | Buy | Buy |
| Apr 16, 2024 | Maxim Group | main | Buy | Buy |
| Nov 17, 2023 | Maxim Group | up | Hold | Buy |
| May 16, 2023 | Ladenburg Thalmann | main | Buy | Buy |
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- palisadebio.com
News
Palisade Bio Analysts Slash Their Forecasts After Q3 Results 
Palisade Bio Analysts Slash Their Forecasts After Q3 Results 
Piper Sandler Maintains Overweight on Palisade Bio, Lowers Price Target to $16 
HC Wainwright & Co. Maintains Buy on Palisade Bio, Lowers Price Target to $5 
Palisade Bio Q3 EPS $(0.07) Misses $(0.06) Estimate 
Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs 
Palisade: Initiating 'Buy' On PALI-2108 UC Study Start And Differentiated PDE4 Inhibitor - Palisade Bio Doses First Patient In Its ASCENTRA-UC Phase 2b Clinical Trial Evaluating PALI-2108 In ~204 Patients With Moderately To Severely Active Ulcerative Colitis; 12-Week Topline Results Expected In Q4 2027
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis 
Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated
Your note
Sign in to keep a note on PALI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CSIMMA CRISTINA | Director | Conversion of Exercise of derivative security | Feb 7, 2024 | 12,862 |
| DIAZ STEPHANIE | Director | Conversion of Exercise of derivative security | Feb 7, 2024 | 12,800 |
| FINLEY JOHN DAVID | Chief Executive Officer | Conversion of Exercise of derivative security | May 27, 2024 | 13,523 |
| JONES MITCHELL LAWRENCE | Officer | Conversion of Exercise of derivative security | May 27, 2024 | 3,852 |
| MCRAE ROBERT CURTIS | Chief Operating Officer | Conversion of Exercise of derivative security | Apr 2, 2023 | 625 |
| NEAL JAMES R | Director | Conversion of Exercise of derivative security | Feb 8, 2024 | 10,920 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 1.88% | 52,000 | 91.00K | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.30% | 8,200 | 14.35K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.06% | 1,597 | 2.79K | Sep 29, 2024 |
| Morgan Stanley | 0.01% | 140 | 245 | Sep 29, 2024 |
| Federation Des Caisses Desjardins Du Quebec | 0.00% | 100 | 175 | Sep 29, 2024 |
| Wells Fargo & Company | 0.00% | 21 | 36 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.23% | 6,330 | 11.08K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.16% | 4,536 | 7.94K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.15% | 4,104 | 7.18K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 2,239 | 3.92K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 1,524 | 2.67K | Oct 30, 2024 |